Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 17/20 | 0.95 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL303564 | 1.00 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973509 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL192828 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7831398 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1268401 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1268399 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1130855 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7751943 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5974480 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7749172 | 0.98 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828435-B2 | Buccal delivery system | LINGUAL CONSEGNA PTY LTD (AU) | 2014-09-09 | — | — | US | claimed |
| EP-2661257-A1 | EFFERVESCENT BISPHOSPHONATE FORMULATIONS | Bilgic, Mahmut (TR) | 2013-11-13 | — | — | EP | claimed |
| WO-2012093978-A1 | EFFERVESCENT BISPHOSPHONATE FORMULATIONS | BILGIC MAHMUT (TR) | 2012-07-12 | — | — | WO | claimed |
| US-20110123619-A1 | BUCCAL DELIVERY SYSTEM | OZPHARMA PTY. LTD. (AU) | 2011-05-26 | — | — | US | claimed |
| US-20080317850-A1 | Buccal Delivery System | OZPHARMA PTY LTD (AU) | 2008-12-25 | — | — | US | claimed |
| EP-1865925-A1 | BUCCAL DELIVERY SYSTEM | Ozpharma PTY Ltd. (AU) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105615-A1 | BUCCAL DELIVERY SYSTEM | OZPHARMA PTY LTD (AU) | 2006-10-12 | — | — | WO | claimed |
| CN-116018131-A | Fast orodispersible tablet with inner cavity | 阿普雷奇亚制药有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11633357-B2 | Liposome formulation and manufacture | ZULI HOLDINGS, LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| EP-3858334-A1 | LIPOSOME FORMULATION AND MANUFACTURE | Zuli Holdings Ltd. (IL) | 2021-08-04 | — | — | EP | disclosed |
| EP-3406240-B1 | LIPOSOME FORMULATION AND MANUFACTURE | ZULI HOLDINGS LTD (IL) | 2021-05-05 | — | — | EP | disclosed |
| CN-107753432-B | Liposome formulations and manufacture | 祖利控股有限公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-111051295-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-04-21 | — | — | CN | disclosed |
| EP-1865925-A1 | BUCCAL DELIVERY SYSTEM | Ozpharma PTY Ltd. (AU) | 2007-12-19 | — | — | EP | disclosed |
| CN-101090887-A | Anthracene derivative, light-emitting element using the same, and light-emitting device using the same | SEMICONDUCTOR ENERGY LAB (JP) | 2007-12-19 | — | — | CN | disclosed |
| CN-1878559-A | Desensitization of complement activation using monocyte/macrophage inhibitory compounds | BIOREST LTD (IL) | 2006-12-13 | — | — | CN | disclosed |
| WO-2006105615-A1 | BUCCAL DELIVERY SYSTEM | OZPHARMA PTY LTD (AU) | 2006-10-12 | — | — | WO | disclosed |
| US-20060153918-A1 | Dosage forms with an enterically coated core tablet | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-13 | — | — | US | disclosed |
| EP-1663167-A1 | DOSAGE FORMS WITH AN ENTERICALLY COATED CORE TABLET | Teva Pharmaceutical Industries Ltd (IL) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006012634-A1 | DOSAGE FORMS WITH AN ENTERICALLY COATED CORE TABLET | TEVA PHARMACEUTICAL INDUDSTRIES, LTD. (IL) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633357-B2 | Liposome formulation and manufacture | LIPA, CLPTM1L, LPXN | FDPS 512/4885PDE3A 1390/4885LMNA 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.